Skip to main content

PERSPECTIVE article

Front. Endocrinol.
Sec. Reproduction
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1501110

Gestational diabetes mellitus and polycystic ovary syndrome, a position statement from EGOI-PCOS

Provisionally accepted
Paola Quaresima Paola Quaresima 1Samuel H Myers Samuel H Myers 2Basilio Pintaudi Basilio Pintaudi 3,4Rosario D'Anna Rosario D'Anna 3,5Michele Morelli Michele Morelli 6Vittorio Unfer Vittorio Unfer 3,7*
  • 1 Department of Obstetrics and Gynecology, Azienda Sanitaria Provinciale di Cosenza, Cosenza, Italy
  • 2 R&D Department, Lo.Li Pharma s.r.l, Rome, Italy
  • 3 The Experts Group on Inositol in Basic and Clinical Research and on PCOS (EGOI-PCOS), Rome, Sicily, Italy
  • 4 ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
  • 5 Department of Human Pathology, University of Messina, Messina, Italy
  • 6 Department of Obstetrics and Gynecology, Annunziata Hospital, Cosenza, Italy
  • 7 Saint Camillus International University of Health and Medical Sciences, Rome, Lazio, Italy

The final, formatted version of the article will be published soon.

    Gestational diabetes mellitus is a worldwide health issue in pregnancy, posing a threat to both mother and child. One of the major risk factors for the development of gestational diabetes mellitus is polycystic ovary syndrome, primarily due to the biochemical hyperandrogenism and metabolic issues, commonly observed in these patients. In recent years, the Expert Group on Inositol in Basic and Clinical Research and on PCOS (EGOI-PCOS) has sought to better understand the pathogenesis behind polycystic ovary syndrome, in order to accurately diagnose and treat patients according to their individual needs. Through the scope of polycystic ovary syndrome, this position paper examines the characteristics of both conditions, and underlying biological mechanisms, before moving on to common treatment strategies to avoid or treat gestational diabetes mellitus in women with polycystic ovary syndrome.

    Keywords: gestational diabetes mellitus, Polycystic Ovary Syndrome, Insulin, Metformin, myo-inositol

    Received: 24 Sep 2024; Accepted: 15 Jan 2025.

    Copyright: © 2025 Quaresima, Myers, Pintaudi, D'Anna, Morelli and Unfer. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Vittorio Unfer, Saint Camillus International University of Health and Medical Sciences, Rome, 00131, Lazio, Italy

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.